

Post Marketing Surveillance Study for Mircera

First published: 10/01/2014

Last updated: 02/07/2024

Study

Finalised

Administrative details

EU PAS number

EUPAS4683

Study ID

20705

DARWIN EU® study

No

Study countries

 Korea, Republic of

Study description

This study (ML22560) is a post-marketing prospective surveillance study (conducted in Korea from 29 Aug 2008 to 28 Aug 2012) to meet local regulatory requirements.

Study status

Finalised

Research institutions and networks

Institutions

[F. Hoffmann-La Roche](#)

First published: 01/02/2024

Last updated: 01/02/2024

Institution

[Multiple centres: 26 centres are involved in the study](#)

Contact details

Study institution contact

Jenny Shin jenny.shin@roche.com

Study contact

jenny.shin@roche.com

Primary lead investigator

Petersen Jenny

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 02/01/2008

Study start date

Actual: 29/08/2008

Data analysis start date

Actual: 28/08/2012

Date of final study report

Actual: 28/11/2012

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

F. Hoffmann-La Roche

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only

Other study registration identification numbers and links

ML22560

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition
Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness
Effectiveness study (incl. comparative)

Data collection methods:

Primary data collection

Main study objective:

The main objectives are to evaluate the following items under routine practice:1) Serious adverse event(AE)/adverse drug reaction (ADR) 2) Unexpected ADR 3) Expected ADR 4) Non-serious AE 5) AE occurred by misuse,

abuse and drug interaction 6) Any factors influencing safety and efficacy parameters (influencing lab. data, etc)

Study Design

Non-interventional study design

Other

Non-interventional study design, other

Prescription event monitoring

Study drug and medical condition

Medicinal product name

MIRCERA

Medical condition to be studied

Anaemia

Population studied

Short description of the study population

Patients who were prescribed Mircera® by their physician according to the local Korean Mircera® label, for the treatment of anemia associated with chronic kidney disease who require Erythropoiesis-Stimulating Agents (ESA) therapy.

Age groups

- Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Special population of interest

Renal impaired

Estimated number of subjects

600

Study design details

Data analysis plan

According to the data, t-test or chi-square test was performed. Adverse events were tabulated in summary tables as followings: Summary table of incidence status of AEs/ADRs by System Organ Class Summary table of drug - adverse events relationship Summary table of Intensity of Adverse events/Adverse Drug Reactions Summary table of Incidence rate Unexpected AEs/ADRs by System Organ Class

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Other

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

Unknown